• Preparing the process with Korea Investment & Securities Co. Ltd. for KOSPI transfer listing


• Strong revenue and profit growth expected following FDA approval of Keytruda Qlex, the subcutaneous version of Keytruda, by Alteogen's partner MSD

DAEJEON, South Korea, Sept. 29, 2025 -- Alteogen Inc. (KOSDAQ:196170) announced today that it has selected Korea Investment & Securities (KIS) as the lead underwriter for its transfer listing to the KOSPI.

In August, the company shared its KOSPI transfer plans with shareholders and investors, and with the appointment of the underwriter, it intends to accelerate the listing process. Alteogen plans to work with KIS on preparations and hold a shareholders’ meeting within the year.

“With the recent FDA approval of Keytruda Qlex, the company anticipates stronger revenue growth and improved profitability in the future. Through the KOSPI transfer listing, we will further elevate our brand presence and create greater value for our shareholders,” said Soon-Jae Park, Ph.D., CEO of Alteogen.

Meanwhile, since its founding in 2008, Alteogen has been developing its pipeline using its proprietary platform technologies such as NexP®, NexMab®, and Hybrozyme®. Current pipeline assets include ALT-B4, ALT-P1, ALT-B5, and ALT-P7. Through its partners and subsidiaries, there are currently four approved products: Keytruda Qlex™, Eyluxvi®, Tergase®, and 安曲妥®.

Among its pipeline, ALT-B4, a human hyaluronidase, enables the conversion of intravenous (IV) formulations of biologics into more convenient and faster subcutaneous (SC) injections. With ALT-B4, Alteogen has signed licensing agreements with global pharmaceutical companies including MSD, AstraZeneca, and Daiichi Sankyo.